NF-κB

Master transcription factor

Expression
Persistently active
Evidence level
strong
Targeted by
Bortezomib (indirect)

Role in pathogenesis

Convergence point — both NLRP3/IL-1β and MYD88 pathways activate NF-κB, which drives inflammatory cytokine production.

Targeting drugs (1)

DrugMechanismResponseLine
BortezomibProteasome inhibitor (NF-κB pathway)Single case reportInvestigational

Sources (2)

DetailsVan Leersum FS et al. (2019) Shared MYD88/NF-κB mechanism hypothesis · Orphanet J Rare DisDOI
DetailsPathak S et al. (2019) MYD88 L265P in 30% of Schnitzler patients · Arthritis RheumatolDOI